摘要
目的:探讨应用草酸铂(L-OHP)与卡培他滨联合方案治疗食管癌转移瘤患者的疗效及安全性,并随访观察中位至疾病进展时间和中位总生存时间。方法:48例食管癌转移瘤患者使用草酸铂130mg/m2,静脉滴注,第1天;卡培他滨1000mg/m2口服,每日2次,第1-14天;每3周为一个周期,至少应用2周期,评价疗效和毒性,并进行随访。结果:48例患者疗效均可评价,完全缓解(CR)2例(4.2%),部分缓解(PR)16例(33.3%),稳定(SD)23例(47.9%),进展(PD)7例(14.6%)。有效率(CR+PR)为37.5%。中位无进展生存期4.5个月,中位生存期8个月。化疗中主要毒副反应为骨髓抑制、消化道反应、神经毒性等。结论:草酸铂联合卡培他滨治疗食管癌转移瘤疗效肯定,毒副反应能耐受,值得进一步研究。
Objective：This study assessed the safety and efficacy of oxaliplatin plus capecitabine in patients with metastatic oesophageal cancer and observed the median time to tumor progression and the median overall survival time by follow up. Mehtods： Forty -eight eligible patients received oxaliplatin 130 mg/m^2 intravenously on day 1 and capecitabine 1000 mg/m^2 orally twice daily on days 1 to 14 in a 21 - day treatment cycle as first - line treatment for metastatic oesophageal cancer. All patients were treated at least two cycles. Results ： overall response rate was 37.5%, with 4.2% complete response （2/48） and 33.3% partial response （16/48）. Stable disease was seen in 47.9% （23/48）, and disease progression in 14.6% （7/48）. Median time to tumor progression was 4.5 months, and median overall survival was 8 months. The major toxicity included myelosuppression, gastrointestinal reaction, nerve toxicity. Conclusion： Oxaliplatin plus capecitabine is effective for the patients with metastatic oesophageal cancer, and its side effect is tolerable.
出处
《现代肿瘤医学》
CAS
2008年第4期575-577,共3页
Journal of Modern Oncology
关键词
草酸铂
卡培他滨
食管癌转移瘤
oxaliplatin
capecitabine
metastatic oesophageal cancer
